Posted 4 февраля 2022, 12:22
Published 4 февраля 2022, 12:22
Modified 24 декабря 2022, 22:38
Updated 24 декабря 2022, 22:38
According to the Ministry of Health, permission to conduct phase III and IV post-clinical trials of the vaccine with the participation of 40,000 people was issued in August 2021. The third phase ended in September. All studies were expected to be completed by the end of the year.
As RBC notes, during the trials, about 10 thousand volunteers were supposed to receive not a drug, but a placebo.
Earlier it was reported that the registration of "Sputnik" abroad began to slip. Among the reasons was called, including insufficient knowledge of the drug. At the same time, representatives of the Russian side insisted that the delay in registering Sputnik is obviously political in nature and may be due to the reluctance of Western partners to launch vaccines on the world market, which turned out to be extremely profitable against the backdrop of the ongoing coronavirus pandemic.
Head of the Center Gamalei Alexander Gintsburg said that citizens under 60 who have already been ill with coronavirus should be revaccinated by Sputnik Light. For older people, Sputnik-V is more suitable.
It's worth reminding that in addition to injectables, the nasal vaccine against COVID-19 was developed by scientists at the Gamaleya National Research Center for Epidemiology and Microbiology. In the spring of 2021, the drug was patented. The director of the center, Alexander Gintsburg, said that no side effects from the nasal vaccine were found during the trials. Note that President Vladimir Putin was vaccinated with this drug. Now children will be vaccinated with this vaccine and used for revaccination.